Cancer

- Read more about Novel cancer drug pass through blood-brain barrier
In efforts to develop new treatments for brain cancer, scientists from Johns Hopkins Drug Discovery and the Kimmel Cancer Center's Bloomberg~Kimmel Institute for Cancer Immunotherapy report they have altered the structure of an experimental drug that seems to enhance its ability to slip through the mostly impermeable blood-brain barrier.
- Read more about FDA Approves Genentech’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab)
Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) approved TECENTRIQ® (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities. This approval is based on results from the randomized Phase III OAK and Phase II POPLAR studies. The largest study, OAK, showed that TECENTRIQ helped people in the overall study population live a median of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy (median overall survival [OS]: 13.8 vs. 9.6 months; HR = 0.74, 95% CI: 0.63, 0.87). The study enrolled people regardless of their PD-L1 status and included both squamous and non-squamous disease types.
- Read more about Cancer Research UK, MSD and Verastem Collaborate to Trial New Combination of Immunotherapy Drugs
MSD, Verastem, Inc. and Cancer Research UK will trial a new combination of immunotherapy drugs in mesothelioma, non small cell lung and pancreatic cancers. The trial will run through the ECMC network at centres in Edinburgh-Dundee, Southampton, Glasgow, Leicester and Belfast.

(adsbygoogle = window.adsbygoogle || []).push({});
- Read more about Synthetic nanoparticles can differentiate lung cancer cells from healthy cells
Researchers with the Harold C. Simmons Comprehensive Cancer Center successfully developed a synthetic polymer that can transport a drug into lung cancer cells without going inside of normal lung cells.

Since conventional chemo drugs indiscriminately kill all rapidly dividing cells to halt the growth of cancer, these selective nanoparticles could decrease side effects by reducing drug accumulation in normal cells.
- Read more about Adverse effect of Afatinib can reduce with dosage monitoring, says Clinical Trial
Results from a new post-hoc analysis of two large phase III trials (LUX-Lung 3 and LUX-Lung 6) assessing the impact of dose adjustments for Giotrif (afatinib) in patients with advanced non-small cell lung cancer (NSCLC) were published in Annals of Oncology. The analysis suggests specific dose reductions, as described in SmPC / prescribing information, led to decreases in the incidence and severity of treatment-related adverse events (AEs) in afatinib-treated patients without any apparent compromise in efficacy.
- Read more about Glucose changes a traditional Chinese medicine into powerful anticancer medicine
More than 20 years ago, a billboard in China piqued the interest of a chemical biologist. It endorsed an extract from the plant known as the "thunder god vine" as an immunosuppressant. A brief review of published research revealed that the extract's key ingredient, the small molecule triptolide, had been identified 20 years before that billboard ad, and it could stop cells from multiplying.
- Read more about Evgen Pharma plc receive CTA for Phase II Study in Breast Cancer
Evgen Pharma plc announced that it has received a Clinical Trial Approval (CTA) from the UK’s regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer.
- Read more about Mitomycin-C improves Bladder Cancer Therapy
Scientists have found that heating the chemotherapy drug mitomycin-C prior to using it for treating bladder cancer may radically improve its efficacy. The findings, published in the International Journal of Hyperthermia, are the result of a four-and-a-half-year study by medics based at Comarcal Hospital, Monforte, Spain.
- Read more about Newly discovered vulnerability in breast tumor cells points to new cancer treatment path
Cancer cells often devise ways to survive even in the presence of toxic chemotherapy. Now, a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has found a way to attack a process that tumor cells use to escape the effects of standard cancer drugs. The discovery is published online today in the journal Nature Cell Biology.
- Read more about New molecular marker can predict breast cancer risk
Researchers have identified a molecular marker that identifies proliferating cells in normal breast tissue and can predict a woman's risk of developing breast cancer, the leading cause of death in women with cancer worldwide.